Valuation: Dimerix Limited

Market Cap 14Cr 9.39Cr 8.34Cr 7.79Cr 7.1Cr 13Cr 902.59Cr 94Cr 37Cr 461.42Cr 35Cr 34Cr 1.48TCr P/E 2025
-24.3x
P/E 2026 -4.13x
Enterprise Value 12Cr 8.28Cr 7.36Cr 6.87Cr 6.26Cr 12Cr 796.21Cr 83Cr 32Cr 407.03Cr 31Cr 30Cr 1.31TCr EV / Sales 2025
49.4x
EV / Sales 2026 16.9x
Free-Float
77.77%
Yield 2025 *
-
Yield 2026 -
1 day-4.26%
Current month-2.17%
1 month-22.41%
3 months-10.00%
6 months-29.69%
Current year-59.09%
1 week 0.22
Extreme 0.225
0.24
1 month 0.22
Extreme 0.225
0.31
Current year 0.16
Extreme 0.157
0.56
1 year 0.16
Extreme 0.157
0.66
3 years 0.1
Extreme 0.096
0.78
5 years 0.05
Extreme 0.052
0.78
10 years 0.05
Extreme 0.052
0.78
Manager TitleAgeSince
Chief Executive Officer - 27/08/2018
Director of Finance/CFO 59 29/01/2026
Chief Tech/Sci/R&D Officer - 01/10/2023
Director TitleAgeSince
Director/Board Member 61 03/07/2015
Chairman - -
Director/Board Member - 27/08/2018
Date Insider Type Main position Quantity % Market Cap. Importance
12/12/25 Free

Chairman

1,00,000 0.0167%
12/12/25 Free

Chairman

1,00,000 0.0167%
12/12/25 Free

Director

1,00,000 0.0167%
Change 5-day change 1-year change 3-year change Capi.($)
-4.26%0.00%-57.94%+262.90% 9.39Cr
+4.16%+3.04%+49.37%+94.17% 7.42TCr
-3.11%-3.53%+21.92%+74.60% 5.74TCr
+0.89%-0.63%+4.28%+34.51% 4.76TCr
+0.36%+0.81%+352.17%+689.61% 4.43TCr
-0.96%-4.50%+26.36%+33.18% 4.25TCr
-0.20%-0.77%+3.74%+100.60% 4.07TCr
-0.54%+2.93%+9.31%+50.41% 3.1TCr
-2.68%+2.92%+29.63%+19.50% 2.85TCr
+0.05%-1.64%-7.28%-14.06% 2.43TCr
Average -0.63%-0.53%+43.16%+134.54% 3.91TCr
Weighted average by Cap. +0.12%-0.84%+58.74%+129.94%

Financials

2025 2026
Net sales 55.87L 38.83L 34.5L 32.2L 29.35L 55.35L 37Cr 3.9Cr 1.51Cr 19Cr 1.46Cr 1.43Cr 61Cr 63.54L 44.16L 39.24L 36.62L 33.38L 62.95L 42Cr 4.43Cr 1.72Cr 22Cr 1.66Cr 1.62Cr 70Cr
Net income -1.33Cr -92.1L -81.83L -76.38L -69.62L -1.31Cr -89Cr -9.24Cr -3.58Cr -45Cr -3.46Cr -3.38Cr -145.27Cr -2.98Cr -2.07Cr -1.84Cr -1.72Cr -1.57Cr -2.95Cr -199.2Cr -21Cr -8.06Cr -101.83Cr -7.78Cr -7.61Cr -326.82Cr
Net Debt -6.82Cr -4.74Cr -4.21Cr -3.93Cr -3.58Cr -6.76Cr -455.58Cr -48Cr -18Cr -232.9Cr -18Cr -17Cr -747.46Cr -1.59Cr -1.11Cr -98.32L -91.77L -83.64L -1.58Cr -106.38Cr -11Cr -4.3Cr -54Cr -4.15Cr -4.06Cr -174.53Cr
Logo Dimerix Limited
Dimerix Limited is an Australia-based clinical-stage biopharmaceutical company focused on developing new therapies for kidney diseases. The Company's lead program, DMX-200, is in Phase III clinical development for focal segmental glomerulosclerosis (FSGS), a serious and life-threatening rare kidney disease with limited treatment options. In addition, it is advancing a Phase II program in acute kidney injury (AKI), further strengthening its pipeline in high-need renal indications. DMX-200 is a chemokine receptor (CCR2) antagonist administered to patients already receiving an angiotensin II type I receptor (AT1R) blocker, the standard of care treatment for hypertension and kidney disease. The Company's DMX-652 is a selective inhibitor of USP30 - a mitochondrial enzyme that slows the removal of damaged mitochondria. The Phase II trial is designed to investigate DMX-652's potential to prevent kidney injury and preserve renal function. It is also developing DMX-700 for respiratory disease.
Employees
15
Date Price Change Volume
02/26/02 A$0.2250 -4.26% 4,02,282
01/26/01 A$0.2350 +2.17% 5,25,796
30/26/30 A$0.2300 0.00% 2,71,613
29/26/29 A$0.2300 -2.13% 3,87,718
28/26/28 A$0.2350 +4.44% 6,86,422